MedTrace Logo

Pilot Study: hCG Secreted by Blastocyst as Potential Marker of Embryo Quality

NCT04736160 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2021-02-04

No results posted yet for this study

Summary

hCG is a hormone produced very early by the pre-embryo, but not by the oocyte. It has a pivotal role in the trophoblast differentiation, and embryo implantation as well as the corpus luteum support. In spite of its well-known role, the literature about it is scarce.

The aim of this study is to evaluate the relation between the amount of hCG secreted by the blastocyst and embryo euploidy status and morphological pre-embryo quality according to morphokinetic pattern.

We will analyse the amount of hCG secreted by blastocyst to the culture medium thorough mass spectrometry and it will be correlated with the main morphokinetic issues and the chromosomal structure after NGS analysis at blastocyst stage.

We will take the pre-embryo spent culture medium that has been discarded after embryo culture without any interference on the pre-embryo neither any different deviation of standard protocol of embryo manipulation. Furthermore, the evaluation by time-lapse technology will let to document the main issues of embryo development, also without any deviation of the standard protocol.

We are waiting to find the value of hCG secreted by blastocyst as a potential marker of embryo quality and ploidy status.

Conditions

  • Embryo Disorder

Interventions

OTHER

collect data

The data for this project will be obtained directly from the IVI digital work platform (SIVIS) where the characteristics and scans performed to each patient are recorded. Furthermore, it will be recollected information from the time-lapse incubator. For the current study will be used Embryoscope and Geri time-lapse incubators

Sponsors & Collaborators

  • Instituto Valenciano de Infertilidad, IVI VALENCIA

    collaborator OTHER

  • IVI Vigo

    lead OTHER

Principal Investigators

  • Elkin Muñoz · IVI Vigo

Eligibility

Min Age
18 Years
Max Age
41 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-05
Primary Completion
2019-11-25
Completion
2021-11-25

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04736160 on ClinicalTrials.gov